Bachem Holding (Suzhou) (revision 40)
Old revision·08:12, 3 May 2025·StubSorterBot
| Bachem Holding (Suzhou) Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Bachem Holding (Suzhou) Co., Ltd. |
| Trading name | BCH |
| Other designations | BCH Biotech, Bachem Holding (Suzhou) |
| Identity | |
| Founded | 2003 |
| Headquarters | Suzhou, China |
| Industry | Research-compound supply |
| Shop domain | Visit BCH |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| PeptidePedia reception tally | |
| Submissions | 838 to July 2026 |
| Evidence quality | Weak — self-selected, self-reported |
| Organisation infobox · conventions | |
Bachem Holding (Suzhou) Co., Ltd. (trading as BCH; bachemholding.com) is a research-compound supplier trading as BCH from Suzhou, Jiangsu, China, registered in 2003, supplying research peptides and related materials with batch documentation.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Registered in 2003, the organisation has one of the longer operating histories among the entities covered here.[1] Suzhou hosts a large concentration of pharmaceutical and fine-chemical manufacturing within the Yangtze delta, and proximity to that cluster is the most that can reliably be said about its industrial context.
The name requires the same treatment as several others on this wiki. "Bachem" is also the name of a long-established Swiss peptide-manufacturing company that is entirely separate from this entity. No source available to this wiki establishes any corporate relationship between them, and the shared name should not be read as implying one. Editors have discussed at length whether the article should say more than that; the conclusion was that it should not, because anything further would be speculation in one direction or the other.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports describe lyophilised material in crimped vials with a batch certificate reporting purity, appearance and, in most cases, water.[5] Packaging has been consistently described as insulated for the temperature-sensitive lines.
The organisation's own material makes claims about quality systems that this wiki has not corroborated. A GMP claim in particular is not a fact until assessed against the applicable framework, and no assessment is available here.[6][2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate, purity and water |
| Research peptides | Repair and secretagogue peptides | Certificate, purity |
| SARMs | Bulk | Certificate, purity |
| Raw materials and oils | Bulk | Certificate, limited detail |
Nothing in the catalogue distinguishes the organisation from its comparators. Its distinguishing features, such as they are, are the length of its registration history and the name coincidence.[2]
Independent testing record
[edit]Submitted reports on BCH material to July 2026 span the incretin range and a set of repair peptides. Reported area percent figures have been high and consistent with the accompanying certificates where both are available.[5]
The set includes one report on a sequence for which no certified reference standard is commercially available. A purity figure obtained without a qualified standard is a statement about relative peak areas and cannot be converted into a potency; that limitation applies to the report and not to the material.[7][8]
Reception
[edit]The PeptidePedia tally records 838 self-reported submissions to July 2026 — among the higher figures on the wiki. Recurring positive themes are certificate completeness and consistency across orders; recurring complaints concern the name confusion.[4] Self-selected; reception rather than quality.[4]
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.
- ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
- ^ ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization.